RegulatoryAlerts Logo
RegulatoryAlerts
InsightsBlogPricingSign InStart Free Trial
All CDSCO (India) updates
CDSCO (India)
NOTICE
Carbimazole related agranulocytosis - Recommendations for the change in Prescribing Information Leaflets (PILs)
Published: 2/17/2026Detected: 9/11/2026

Summary preview

Recommends updates to the Prescribing Information Leaflets (PILs) for carbimazole-containing products to address the safety risk of agranulocytosis associated with use.

Get the full analysis, free

Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.

Create free account
safety
labeling
hematology
#India CDSCO
#carbimazole
#agranulocytosis
#Prescribing Information Leaflet
#labeling update

Official Source Document
Source Verified

Access the original document directly from INDIA CDSCO.

View Official Document

More from CDSCO (India)

  • Indiscriminate use of painkillers (NSAIDs), antibiotics and associated risk of Chronic Kidney Disease9/22/2026
  • LIST OF REGISTRED BA-BE STUDY CENTRE & BIO-ANALYTICAL LABORATORY under NDCT Rules 20199/18/2026
  • Public Health alert against the use of unauthorised Cosmetics Products9/14/2026
  • 2026.09.08 G.S.R. 791(E)_Draft notification for amendment in the Drugs Rules 1945 regarding mandatory installation of CCTV surveillance system at sales premises9/8/2026
  • Drug Regulatory and Law Enforcement Agencies Intensify Coordinated Action Against Illegal Manufacture and Distribution of Misbranded Drugs9/5/2026

Get CDSCO (India) alerts in your inbox as they are published.

Free plan, 2-minute setup, no credit card required.

RegulatoryAlerts Logo
RegulatoryAlerts

Automated regulatory intelligence monitoring for pharmaceutical and biotech professionals. Track FDA, EMA, and Health Canada updates seamlessly.

Product

  • Insights
  • Updates by Therapeutic Area
  • FDA Updates
  • EMA Updates
  • Pricing
  • Features
  • Request Demo

Resources

  • Integration Guides
  • Regulatory Glossary
  • EMA Timeline
  • Best Practices
  • Therapeutic Areas

Company

  • About Us
  • Blog
  • Contact
  • Security
  • Privacy Policy
  • Terms of Service

    • © 2026 RegulatoryAlerts. All rights reserved.

    Not affiliated with the FDA, EMA, or Health Canada.